- $663.72m
- $286.05m
Biotech stocks tumble on reports FDA's top vaccine regulator to leave
Gene therapy makers slide on reports that FDA official Peter Marks resigns
Solid Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary
Solid Biosciences Inc expected to post a loss of 60 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-General Mills, Meta Platforms, Domino's Pizza
Solid Biosciences jumps on early-stage data from gene therapy
Brief: Solid Biosciences Announces Pricing Of Underwritten Offering
Brief: Solid Biosciences Reports Positive Initial Clinical Data from SGT-003
Brief: Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Brief: Solid Biosciences Outlines Key Priorities For Advancing Diversified Neuromuscular And Cardiac Development Pipeline
Brief: Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia
Brief: Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Solid Biosciences Added To The Nasdaq Biotechnology Index
Brief: Solid Biosciences Announces Collaboration With Mayo Clinic To Accelerate Gene Therapy Innovation And Advance Development Of Cardiac Gene Therapies
Solid Biosciences Inc reports results for the quarter ended in September 30 - Earnings Summary
Solid Biosciences Inc expected to post a loss of 67 cents a share - Earnings Preview
Brief: Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Solid Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Solid Biosciences Inc expected to post a loss of 65 cents a share - Earnings Preview